|
|
Vaccine Detail
|
Lassa fever Virus Ad5 (E1-, E2b-) Vectored Vaccine |
| Vaccine Information |
- Vaccine Name: Lassa fever Virus Ad5 (E1-, E2b-) Vectored Vaccine
- Target Pathogen: Lassa Fever Virus
- Target Disease: Lassa fever
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: None
- Antigen: Lassa Virus NP, GPC (Maruyama et al., 2019)
- Preparation: The deletion in the structural E1 gene and E2b gene render the vector non-replicative and deletions in the E3 gene allow the vector to be effective even in the presence of pre-existing Ad5 immunity. The LASV GPC or LASV NP were inserted into the Ad5 (E1-, E2b-) vector based platform. The product was then amplified in E.C7 cells, (HEK293 cells) which constitutively express the Ad polymerase and preterminal protein, before undergoing concentration and purification. (Maruyama et al., 2019)
- Immunization Route: Intramuscular injection (i.m.)
- Description: An adenovirus vectored vaccine encoding lassa virus NP and GPC providing protection in guniea pig model. (Maruyama et al., 2019)
|
| Host Response |
|
|
| References |
|
|
|
